

This erratum sheet lists errors and their corrections for the doctoral thesis of Sandra Soeria-Atmadja, titled “Efavirenz therapy in children living with HIV-the role of pharmacogenetics for plasma level variation and treatment results”, Karolinska Institutet, Stockholm, Sweden, 2024, ISBN 978-91-8017-762-7.

Thesis	
Page 14	Error: "...can detect genotypic resistant if < 15-20%"
Paragraph 1	Correction: "...can detect genotypic resistant if > 15-20%"
Page 17	Error: "...and its metabolites Ugandan..."
Paragraph 1	Correction: "...and its metabolites in Ugandan..."
Page 17	Error: "...a selection of phase I and phase II metaboliteplasma profiles in..."
Paragraph 3	Correction: "...a selection of phase I and phase II metabolites in..."
Page 22	Error: "...defined as VL<50 cop."
Paragraph 2	Correction: "...defined as VL <50 cop/ml before 2007 and thereafter as VL<20 cop/ml."
Page 23	Error: "Quantification of EFV concentration in plasma ALB-cohort"
Paragraph 2	Correction: "Quantification of EFV concentration in plasma"
Page 23	Error: "...collected in EDTA using ç..."
Paragraph 3	Correction: "...collected in EDTA using..."
	Error: "...was carried out in at..."
	Correction: "...was carried out at..."
Page 25	Error: "...and visits, were with median (IQR)"
Paragraph 8	Correction: "...and visits, was described with median (IQR)"
Page 26	Error: Missing section "Methods study IV" following 3.3.4
	Correction:
	Methods study IV
	The definitions of viral suppression and HIV drug resistance before and after 24 weeks of treatment are outlined in 3.3.2.3. Participants were categorized into four immunodeficiency levels—none, mild, advanced, or severe—based on CD4 levels in accordance with WHO standard [122]. All baseline samples were tested for pretreatment drug resistance. If sequencing failed, results were classified as missing. At week 24, only samples with a viral load (VL) ≥ 500 copies/mL were sequenced. Children with a VL < 500 copies/mL and no detected PDR were considered free of HIVDR for the week 24 analysis. In contrast, all children with PDR were presumed to still carry baseline drug resistance mutations (DRMs), even if they had achieved viral suppression by week 24. The association between baseline characteristics (gender, age, immunodeficiency, initial viral load level, mean adherence, pretreatment HIVDR) and 24-week outcomes, including virologic suppression and the emergence of new HIVDR mutations were assessed through logistic regression analysis.

	Variables found to be statistically significant in univariable logistic regression were further evaluated in a multivariable model.
Page 35	Error: CYP2A6*9 (rs28399433), “AA”, ALB cohort: 81%
Table 4	Correction: CYP2A6*9 (rs28399433), “AA”, ALB cohort: 80%
Page 35	Error: CYP2B6 g. 15582C>T (rs4803419), “CC”, GENEFA: 88%
Table 4	Correction: CYP2B6 g. 15582C>T (rs4803419), “CC”, GENEFA: 89%
Page 36	Error: “All”, >4000 ng/ml (%): 23,7%
Table 5	Correction: “All”, >4000 ng/ml (%): 22,7%
Page 51	Error: “...the CYP2B6 g.15582C>T/T genotype, (CYP2B6*11 A/G), and...”
Paragraph 4	Correction: “...the CYP2B6 g.15582C>T/T genotype, CYP2B6*11 A/G genotype (CYP2B6 c.136A>G), and...”
Page 55	Error: Sentence “Viremia at week 24 was strongly associated...children with PDR (133)” should be removed. The sentence that follows is correct.
Paragraph 2	Correct: “Viremia at week 24 was significantly associated with...viral failure (134)”
Page 73	Error: Missing reference. ”World Health Organization. The WHO Case Definitions of HIV for Surveillance and the Revised Clinical Staging and Immunological Classification of HIV-related Disease.”
	Correction: Added to references and referred to as (122) in corrections page 26.
Study II	
Table 2	Error: CYP2B6 g.-82T>C , (rs34223104), “TT”: 91,9%
	Correction: CYP2B6 g.-82T>C , (rs34223104), “TT”: 91,7%
	Error: CYP2B6 g. 15582C>T (rs4803419), “CC”, GENEFA: 88%
	Correction: CYP2B6 g. 15582C>T (rs4803419), “CC”, GENEFA: 88,6%
	Error: ABCB1 c3435G>A (rs1045642), “AA”: 1,03% and “AG”: 17,5%
	Correction: ABCB1 c3435G>A (rs1045642), “AA”: 1% and “AG”: 17,6%
	Error: ABCB1 c.4036T>C rs3842, “TT”: 60,8%
	Correction: ABCB1 c.4036T>C rs3842, “TT”: 60,9%
	Error: SM, “Frequency %”: 15,5 %
	Correction: SM, “Frequency %”: 15,4 %
Study III	
Page 8	Error: “..between EM and IM (p=0,008) adjusted for multiple...(table 1)”
Row 266	Correction: “..between EM and IM (p=0,008) adjusted for multiple...(data not shown)”
Page 12	Error: “..in 30% of individuals...(60)”, (incorrect citation).
Row 394	Correction: “..in 30% of individuals...(24)”